United Press International - Health Business News Archive
Comprehensive reports and health tips written by our well-known experts.
http://www.upi.com/rss/feedhome/upi_HealthBusiness.rss
Page: 1 of 27 
- Vioxx plaintiffs wrap up arguments
- Dems cool on White House flu plan
- Gulf War Syndrome recognized in U.K.
- Trials stopped early warrant skepticism
- Cigna expands health savings plan
- Lawmaker pushes counterfeit drug bill
- Groups urge FDA action on Plan B
- Bush unveils U.S. flu readiness plan
- Helper drug could double Tamiflu supply
- HMO says software cuts hospital denials
- Security, privacy a health IT concern
- J&J rethinking Guidant buyout
- Tm Bioscience developing bird flu test
- FDA: Electronic drug labels now required
- Poll: Pharma needs more regulation
- Barr to vote on PETA animal testing motion
- Bill creates national disability insurance
- HHS releases pandemic-flu plan
- Health costs a top concern of CEOs
- Men with testicular cancer fertile -- BBC
- Merck prevails in 2nd Vioxx suit
- Officials prepare for Medicare Part D
- Health-program cuts pass in Senate budget
- Plavix for heart attacks could save lives
- FDA, firms team on liver toxicity
- Health group urges flu plan funding
- U.S. leads in medical errors -- study
- Lawmakers try forcing FDA on Plan B
- Grassley praises discount drug plans
- GAO: Flu-vaccine shortage offers lessons
- Biomist's disinfectant kills norovirus
- Health IT needs wiggle room -- official
- Vioxx trials could be bad for industry
- MD helpers might cut hospital readmission
- FDA tentatively OKs generic AIDS drug
- Ligand morphine drug gets alcohol warning
- MD assistants get expanded role in U.K.
- U.K. toys possibly toxic?
- Health IT needs wiggle room -- official
- FDA fast-tracks prostate-cancer drug
- Guidant can likely force J&J sale
- U.K. drug cleared for severe asthma
- HMO sued over dwarfism therapy
- AMA issues quarantine guidelines
- Analysts split on J&J's Guidant buyout
- Medicare drugs replace charity
- AMA docs assail CMS reporting plan
- French malaria vaccine shows promise
- Medicare cuts will cause docs to flee
- AMA: smoke ban needed in U.S. workplace
- Genentech eye drug shines in studies
- Drug firm Serono may go on block
- Microchip can identify lethal flu strains
- Syphilis, Chlamydia increased in 2004
- Flumist may benefit from flu-pandemic plan
- FDA extends privacy pact with Europe
- Experts downplay pandemic flu risk
- Rural docs helped by Medicare reform
- FDA extends privacy deal with EU
- Health Net settles suit amid bad press
- FDA clears Boston Scientific's pain device
- Study:make worker flu shots mandatory
- Biotech pushes bill to expand SBA grants
- Novartis iron overload drug OK'd
- ER docs: Hospitals not ready for flu surge
- Colon-cancer screening costs may rise
- Humana faces tough Pa. rivals
- Privacy groups challenge HIPAA protections
- Study: Public misled by depression ads
- Survey shows low backing for Medicare Rx
- National health IT system taking off
- FDA OKs stem cells for heart study
- Makers of unapproved treatments warned
- Cancer detection device developed
- Study looks positive for pancreatic cancer
- Medimmune FluMist gets CDC endorsement
- CDC denies 1918 flu-bug trip
- Report offers tips to stem pandemics
- St. Jude Medical cleared to buy ANS
- FDA warns of hormone patch's clotting risk
- Next Vioxx suits limited to long-term use?
- Imclone CEO resigns
- Condoms may get new warnings
- House bill cutting Medicaid stalls
- Pediatricians 2nd biggest drug ad target
- Study gives tips for improving trials
- CMS says no rush on Medicare drug plan
- Abbott heart drug lukewarm in studies
- FDA OKs new use for Merck antibiotic
- Same-day angioplasty cuts costs
- GAO calls FDA actions on Plan B 'unusual'
- Novel compounds kill breast-cancer cells
- Aspirin use down in arthritis patients
- FDA mulls Boston Scientific stent snag
- Pharma working with FBI to stop activists
- New test can detect heart failure earlier
- J&J to buy Guidant at reduced price
- Zocor paces Lipitor in study
- Crestor combo cuts bad cholesterol 65 percent
- Pfizer smoke drug bests Zyban